Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...

Despite disruptions and restructuring costs, Sarepta Therapeutics Inc (SRPT) showcases strong revenue performance and ...

Major U.S. equities indexes were lower at midday Tuesday, with Palantir Technologies leading tech stocks lower.

Shares plunge 36% after nine-year DMD drug trial misses endpoint. Q3 revenue beats but clinical failure dominates sentiment.

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Sarepta Therapeutics delivered a disastrous third-quarter earnings performance. A long-delayed confirmatory clinical trial of ...

The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...